Hi, what are you looking for?
Oramed has screened the first patients in its global Phase 3 trials of its oral insulin capsule for the treatment of type 2 diabetes.
Oramed Signs up to $50 Million Licensing and Investment Agreements for Oral Insulin Capsule in China, Hong Kong and Macau
Sinopharm Capital-Hefei Signs Letter of Intent with Oramed for $50 million Investment and Licensing Deal in China
– – Israeli startup Oramed Pharmaceuticals, a developer of oral drug delivery systems, has been granted by the Russian Federal Service for Intellectual Property...
– – Israeli startup Oramed Pharmaceuticals, a developer of oral drug delivery systems, announced that it entered into purchase agreements with several institutional investors...
The Israel Patent Office has granted Israel’s Oramed Pharmaceuticals, a developer of oral drug delivery systems, a patent for its invention, titled “Methods and...
Israel’s Oramed Pharmaceuticals, a developer of oral drug delivery systems, confirmed that it has received $5 million in connection with the definitive agreement with...
– Insulin tablet developer Oramed Pharmaceuticals has published a draft prospectus. – – Insulin tablet developer Oramed Pharmaceuticals Inc. (Nasdaq:ORMP) has published a draft prospectus to...
Oravax Medical, Oramed subsidiary, signed an agreement with Vietnam’s Tan Thanh Holdings Investment Joint Stock Company to prepurchase ten million doses of Oravax’s oral...
The company just raised $25 million.